According to the report published by Visiongain, the Antinuclear Antibody (ANA) market was valued at approximately USD 987.1 million in 2019 and is expected to generate around USD 14.7 billion by 2030, at a CAGR of around 9.7% between 2020 and 2030.
The sample of antinuclear antibody (ANA) is commonly used as an autoimmune disease serological indicator. Antinuclear antibodies are immunoglobulins or antibodies that attach within the nucleus of natural cells to one or more antigens. The ANA test can be a helpful laboratory instrument used selectively to assist verify or exclude chronic rheumatic disease identification. However, as well as good people, the comparatively elevated incidence of ANAs in other inflammatory circumstances can render it hard to understand a favorable outcome.
Anti-nuclear antibodies (ANAs), also recognized as an anti-nuclear force or ANF, are blood-borne autoantibodies generated by the immune system that also invade the body’s own tissues by working against one or more proteins in the body. Normally, the body generates antibodies to assault and kill objects or external objects such as viruses and bacteria. ANAs are unusual antibodies or autoantibodies with the ability to bind and work against the skin to different areas of the nucleus of the cells. The immune system’s inclination to operate against its own tissue is called autoimmunity. Thus, when identified, AANAs may indicate the existence of autoimmune disease. Disorder is autoimmune diseases.
Autoimmune diseases are characterized by inflammation of different bodily tissues. ANAs are discovered in people with various autoimmune diseases, including systemic Lupus erythematosus, drug-induced lupus, Sjogren’s syndrome, rheumatoid arthritis, scleroderma, vitiligo, Hashimoto thyroiditis, juvenile diabetes mellitus, additive illness, pernicious anemia, glomerulonephritis, and lung fibrosis. In addition, ANAs can be discovered in people with circumstances not deemed to be typical autoimmune diseases like cancer and acute infections. The ANA elisa test detects the serum autoantibodies. Autoantibody screening is useful in the diagnosis of autoimmune disorders and monitoring levels helps to predict the progression of diseases or assessing the efficacy of a treatment.
Why you should buy Antinuclear Antibody (ANA) Market Forecast 2020-2030: Forecasts and Analysis by and Geography, with Profiles of Leading Companies
What is the future of the Antinuclear Antibody (ANA) market? Visiongain’s comprehensive analysis contains highly quantitative content delivering solid conclusions benefiting your analysis and illustrates new opportunities and potential revenue streams helping you to remain competitive. This definitive report will benefit your decision making and help to direct your future business strategy.
We guarantee in this 171 page report you will receive the following key information –
– View Antinuclear Antibody (ANA) market forecasts and analysis from 2020-2030 to keep you ahead of your competitors and ensure you exploit key business opportunities
– The report provides detailed sales projections of the market, the competitors, and the commercial drivers and restraints allowing you to more effectively compete in the market. In addition to market forecasts from 2020-2030, our new study shows current market data, original critical analysis, and revealing insight into commercial developments
– Antinuclear Antibody (ANA) revenue forecast
– Antinuclear Antibody (ANA) connections forecast
A important stage in the diagnosis of chronic lupus erythematosus (SLE) and other chronic autoimmune rheumatic diseases (SARD) is testing for the existence of antinuclear antibodies (ANAs). The conventional slide-based external immunofluorescence (IIF) experiment is commonly used, but is restricted by a comparative absence of SLE specificity and is not identified by all SARD-ANAs. Alternative immunoassays that could provide improved data on diagnosis and prognosis have developed, some of which have joined clinical exercise. This analysis summarizes the present state of ANA screening and multiplexing methods to detect other autoantibodies, the potential for point-of-care testing, and application methods.
– Examine 122 tables, charts, and graphs.
– Let our analysts present you with a thorough assessment of the current and future ANA market prospects.
– This analysis will achieve quicker, easier understanding. Also you will gain from our analyst’s industry expertise allowing you to demonstrate your authority on the Antinuclear Antibody (ANA) sector
– Discover sales predictions for the key end use submarkets from 2020-2030
– What are the dynamics of the Antinuclear Antibody (ANA) industry? Which submarkets will generate the most revenue? Use our forecasts and expert insight to grow your business and give you more industry influence. Find where you can gain and how your organisation can succeed. Avoid falling behind. Stay informed about the potential for each of these Antinuclear Antibody (ANA) submarkets with individual forecasts and analysis from 2020-2030.
– Product submarket forecast 2020-2030
– Technique submarket forecast 2020-2030
– Application submarket forecast 2020-2030
– Learn about the market prospects for the leading Antinuclear Antibody (ANA) market segments 2020-2030
– How will various value chain members perform over the forecast period? Discover where the highest revenue potential lies from 2020-2030, learning about how Antinuclear Antibody (ANA) revenue trickles down through the various market segments. These forecasts will also reveal the competitive landscape. You will see what is happening, explaining the challenges, trends, competitors, and market opportunities. Our report reveals forecasts for the 3 leading segmentations as follows.
– Product Revenue Forecast 2020-2030
– Reagents & Assay Kits revenue forecast 2020-2030
– Systems revenue forecast 2020-2030
– Software & Services revenue forecast 2020-2030
– Other Product revenue forecast 2020-2030
– Technique Revenue Forecast 2020-2030
– ELISA revenue forecast 2020-2030
– Immunofluorescence Assay revenue forecast 2020-2030
– Multiplex Assay revenue forecast 2020-2030
– Other Technique revenue forecast 2020-2030
– Application Revenue Forecast 2020-2030
– Rheumatoid Arthritis revenue forecast 2020-2030
– Systemic Lupus Erythematosus revenue forecast 2020-2030
– Sjogren’s Syndrome revenue forecast 2020-2030
– Scleroderma revenue forecast 2020-2030
– Other revenue forecast 2020-2030
– Understand the prospects for the 4 regional and the leading 12 national Antinuclear Antibody (ANA) markets – where will the highest revenues and opportunities occur?
– Learn about the market potential for Antinuclear Antibody companies in the developed and developing countries, from 2019 onwards. You will see where and how opportunities exist with revealing individual market forecasts and analysis from 2020-2030 for 12 leading national markets by revenue, as well as segmented regional forecasts
– North America Antinuclear Antibody (ANA) revenue forecast 2020-2030
– US Antinuclear Antibody (ANA) revenue forecast 2020-2030
– Canada Antinuclear Antibody (ANA) revenue forecast 2020-2030
– Mexico Antinuclear Antibody (ANA) revenue forecast 2020-2030
– North America Antinuclear Antibody (ANA) by Product revenue forecast 2020-2030
– North America Antinuclear Antibody (ANA) by Technique revenue forecast 2020-2030
– North America Antinuclear Antibody (ANA) by Application revenue forecast 2020-2030
– Asia Pacific Antinuclear Antibody (ANA) revenue forecast 2020-2030
– China Antinuclear Antibody (ANA) revenue forecast 2020-2030
– Japan Antinuclear Antibody (ANA) revenue forecast 2020-2030
– India Antinuclear Antibody (ANA) revenue forecast 2020-2030
– Australia Antinuclear Antibody (ANA) revenue forecast 2020-2030
– Rest of Asia Pacific Antinuclear Antibody (ANA) revenue forecast 2020-2030
– Asia Pacific Antinuclear Antibody (ANA) by Product revenue forecast 2020-2030
– Asia Pacific Antinuclear Antibody (ANA) by Technique revenue forecast 2020-2030
– Asia Pacific Antinuclear Antibody (ANA) by Application revenue forecast 2020-2030
– European Antinuclear Antibody (ANA) revenue forecast 2020-2030
– Germany Antinuclear Antibody (ANA) revenue forecast 2020-2030
– UK Antinuclear Antibody (ANA) revenue forecast 2020-2030
– France Antinuclear Antibody (ANA) revenue forecast 2020-2030
– Italy Antinuclear Antibody (ANA) revenue forecast 2020-2030
– Spain Antinuclear Antibody (ANA) revenue forecast 2020-2030
– Rest of Europe Antinuclear Antibody (ANA) revenue forecast 2020-2030
– European Antinuclear Antibody (ANA) by Product revenue forecast 2020-2030
– European Antinuclear Antibody (ANA) by Technique revenue forecast 2020-2030
– European Antinuclear Antibody (ANA) by Application revenue forecast 2020-2030
– Rest of World Antinuclear Antibody (ANA) revenue forecast 2020-2030
– Rest of World Antinuclear Antibody (ANA) by Product revenue forecast 2020-2030
– Rest of World Antinuclear Antibody (ANA) by Technique revenue forecast 2020-2030
– Rest of World Antinuclear Antibody (ANA) by Application revenue forecast 2020-2030
– Explore the factors affecting Antinuclear Antibody (ANA) product developers, and everyone within the value chain. Learn about the forces influencing market dynamics.
– Discover what the present and future outlook for business will be. Learn about the following business critical issues
– Research and development (R&D) strategy
– Technological issues and constraints.
– Competition from new product types
– Increasing specialisation by leading players
– Increasing industry consolidation.
– Advances in product quality
– Analysis of barriers to entry
– Identify who the leading companies are in the Antinuclear Antibody (ANA) industry
– Our report reveals the technologies and companies which hold the greatest potential. In particular, exploring and analyzing the activities of these companies: See where the expected gains will be. View visiongain’s assessment of the prospects for established competitors, rising companies, and new market entrants. Our work explains that potential, helping you stay ahead. Gain a thorough understanding of the competitive landscape with profiles of 10 leading Antinuclear Antibody (ANA) companies examining their positioning, capabilities, product portfolios, R&D activity, services, focus, strategies, M&A activity, and future outlook.
Leading Companies in the Global Antinuclear Antibody (ANA) Market
Euroimmun AG
Erba Diagnostics, Inc
Bio-Rad Laboratories, Inc
Trinity Biotech PLC
Zeus Scientific, Inc.
Inova Diagnostics
Immuno Concepts
Alere Inc.
Thermo Fisher Scientific, Inc.
Eagle Biosciences
Discover Information found nowhere else in this independent assessment of the Antinuclear Antibody (ANA) market
The Antinuclear Antibody (ANA) Market Forecast 2020-2030: Forecasts and Analysis By Product, By Technique, By Application and Geography, with Profiles of Leading Companies, with Profiles of Leading Companies report provides impartial Antinuclear Antibody (ANA) sector analysis. With the independent business intelligence found only in our work, you will discover where the prospects are for profit. In particular, our new research provides you with key strategic advantages: Our informed forecasts, independent and objective analysis, exclusive interviews and revealing company profiles will provide you with that necessary edge, allowing you to gain ground over your competitors.
With this report you are less likely to fall behind in knowledge or miss crucial business opportunities. You will save time and receive recognition for your market insight. See how you this report could benefit and enhance your research, analysis, company presentations and ultimately your individual business decisions and your company’s prospects.
What makes this report unique?
Visiongain’s research methodology involves an exclusive blend of primary and secondary sources providing informed analysis. This methodology allows insight into the key drivers and restraints behind market dynamics and competitive developments. The report therefore presents an ideal balance of qualitative analysis combined with extensive quantitative data including global, submarket and regional markets forecasts from 2020-2030
How the Antinuclear Antibody (ANA) Market Forecast 2020-2030: Forecasts and Analysis By Product, By Technique, By Application and and Geography, with Profiles of Leading Companies report can benefit you
Visiongain’s report is for anyone requiring analysis of the Antinuclear Antibody (ANA) market. You will discover market forecasts, technological trends, predictions and expert opinion providing you with independent analysis derived from our extensive primary and secondary research. Only by purchasing this report will you receive this critical business intelligence revealing where revenue growth is likely and where the lucrative potential market prospects are. Don’t miss this key opportunity to gain a competitive advantage.
Avoid falling behind your competitors, overlooking critical business opportunities or losing industry influence. In our new report you will discover forecasts from 2020-2030 at the global, submarket, and national level. The report also assesses technologies, competitive forces and expected product pipeline developments. Read on to discover the prospects for the Antinuclear Antibody (ANA) sector and find out what its future market prospects are.
If you buy our report today your knowledge will stay one step ahead of your competitors. Discover how our report could benefit your research, analyses and strategic decisions, saving you time. To gain an understanding of how to tap into the potential of this market and stay one step ahead of the competition you must order now our report the Antinuclear Antibody (ANA) Market Forecast 2020-2030: Forecasts and Analysis By Product, By Technique, By Application and Geography, with Profiles of Leading Companies, with Profiles of Leading Companies report provides impartial Antinuclear Antibody (ANA) sector analysis. Avoid missing out – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
Report Overview
1.1 Global Antinuclear Antibody (ANA) Test Market Definition
1.2 Global Antinuclear Antibody (ANA) Test Market Overview
1.3 Global Antinuclear Antibody (ANA) Test Market Segmentation
1.4 Research Scope of Antinuclear Antibody (ANA) Test in the Industry
1.5 Why You Should Read This Report
1.6 How This Report Delivers
1.7 Key Questions Answered by This Analytical Report
1.8 Methodology
1.8.1 Secondary Research
1.8.2 Market Evaluation & Forecasting Methodology
1.9 Frequently Asked Questions (FAQ)
1.10 Associated Visiongain Reports
1.11 About Visiongain
2. Introduction to Antinuclear Antibody (ANA) Test Systems Market
2.1 Market Definition
2.2 Industry Outlook
2.3 Value Chain Analysis
2.4 Industry Structure
2.5 Current Status & Trends
2.6 Demand & Supply Analysis
2.7 Trade Analysis
2.8 Price Trend Analysis
2.9 Materials Provided
2.9.1 ANA Antigen Substrate Slides
2.9.2 Fluorescent Antibody Conjugate
2.9.3 Positive Control Serum
2.9.4 Negative Control Serum
2.9.5 Phosphate Buffered Saline (PBS)
2.5.6 Mounting Medium
3. Global Antinuclear Antibody (ANA) Test Market Analysis
3.1 PEST Analysis of the Antinuclear Antibody (ANA) Test Market
3.2 Expert Opinion
3.2.1 Primary Correspondents
3.3 Market Outlook
3.4 Drivers & Restraints
3.4.1 Growth in the Number of Individuals Covered Under Medical Insurance
3.4.2 Increasing Population and Growth in Healthcare Expenditure
3.4.3 High Incidence of Autoimmune Diseases
3.4.4 Stringent Regulations for the Approval of Medical Devices
3.4.5 Emerging Markets in Asia Present High-Growth Opportunities
3.5 Dominant Region/Country
3.6 Market Scenario
3.7 Overall Growth Rate, Globally
3.8 SWOT Analysis of the Antinuclear Antibody (ANA) Test Market
3.8.1 Strengths
3.8.2 Weaknesses
3.8.3 Opportunities
3.8.4 Threats
3.9 Porter’s Five Forces Analysis
3.9.1 Competitive Rivalry
3.9.1.1 Powerful Competitive Strategy
3.9.1.2 Firm Concentration Ratio
3.9.1.3 Degree Of Transparency
3.9.2 Supplier Power
3.9.2.1 Supplier Switching Costs Relative To Firm Switching Costs
3.9.2.2 Supplier Concentration To Firm Concentration Ratio
3.9.2.3 Degree Of Differentiation Of Inputs
3.9.3 Buyer Power
3.9.3.1 Degree Of Dependency Upon Existing Channels Of Distribution
3.9.3.2 Buyer Switching Costs Relative To Firm Switching Costs
3.9.3.3 Buyer Concentration To Firm Concentration Ratio
3.9.4 Threat Of Substitute
3.9.4.1 Buyer Propensity To Substitute
3.9.4.2 Relative Price Performance Of Substitute
3.9.4.3 Perceived Level Of Product Differentiation
3..9.5 Threat Of New Entrant
3.9.5.1 Economies Of Scale
3.9.5.2 Switching Costs Or Sunk Costs
3.9.5.3 Industry Profitability (Market CAGR)
4. Antinuclear Antibody (ANA) Test: Global Market Analysis by Segments
4.1 Global Antinuclear Antibody (ANA) Test Market Forecast, by Product 2020-2030
4.1.1 Product Overview
4.1.2 Reagents & Assay Kits Market Forecast, 2020-2030
4.1.3 Systems Market Forecast, 2020-2030
4.1.4 Software & Services Market Forecast, 2020-2030
4.1.5 Other Product Market Forecast, 2020-2030
4.2 Global Antinuclear Antibody (ANA) Test Market Forecast, by Technique 2020-2030
4.2.1 Technique Overview
4.2.2 ELISA Market Forecast, 2020-2030
4.2.3 Immunofluorescence Assay Market Forecast, 2020-2030
4.2.4 Multiplex Assay Market Forecast, 2020-2030
4.2.5 Other Technique Market Forecast, 2020-2030
4.3 Global Antinuclear Antibody (ANA) Test Market Forecast, by Application 2020-2030
4.3.1 Application Overview
4.3.2 Rheumatoid Arthritis Market Forecast, 2020-2030
4.3.3 Systemic Lupus Erythematosus Market Forecast, 2020-2030
4.3.4 Sjogren’s Syndrome Market Forecast, 2020-2030
4.3.5 Scleroderma Market Forecast, 2020-2030
4.3.6 Other Application Market Forecast, 2020-2030
4.4 Global Antinuclear Antibody (ANA) Test Market Forecast, by End-Use 2020-2030
4.4.1 End-Use Overview
4.4.2 Hospitals Market Forecast, 2020-2030
4.4.3 Clinical Laboratories Market Forecast, 2020-2030
4.4.4 Physician Office Laboratories Market Forecast, 2020-2030
4.4.6 Other Application Market Forecast, 2020-2030
5. Leading Regions in Antinuclear Antibody (ANA) Test Market 2020-2030
5.1 Regional Overview
5.1.1 North America
5.1.2 Europe
5.1.3 Asia Pacific
5.1.4 LAMEA
5.1.5 Leading Countries/ Regions
5.2 North America Antinuclear Antibody (ANA) Test Market Forecast, 2020-2030
5.2.1 North America Antinuclear Antibody (ANA) Test Submarket, By Product Forecast 2020-2030
5.2.2 North America Antinuclear Antibody (ANA) Test Submarket, By Technique Forecast 2020-2030
5.2.3 North America Antinuclear Antibody (ANA) Test Submarket, By Application Forecast 2020-2030
5.2.4 North America Antinuclear Antibody (ANA) Test Submarket, By Country Forecast 2020-2030
5.2.4.1 U.S. Antinuclear Antibody (ANA) Test Market, Forecast 2020-2030
5.2.4.2 Canada Antinuclear Antibody (ANA) Test Market, Forecast 2020-2030
5.2.4.3 Mexico Antinuclear Antibody (ANA) Test Market, Forecast 2020-2030
5.3 Europe Antinuclear Antibody (ANA) Test Market Forecast, 2020-2030
5.3.1 Europe Antinuclear Antibody (ANA) Test Submarket, By Product Forecast 2020-2030
5.3.2 Europe Antinuclear Antibody (ANA) Test Submarket, By Technique Forecast 2020-2030
5.3.3 Europe Antinuclear Antibody (ANA) Test Submarket, By Application Forecast 2020-2030
5.3.4 Europe Antinuclear Antibody (ANA) Test Submarket, By Country Forecast 2020-2030
5.3.4.1 U.K. Antinuclear Antibody (ANA) Test Market, Forecast 2020-2030
5.3.4.2 Germany Antinuclear Antibody (ANA) Test Market, Forecast 2020-2030
5.3.4.3 France Antinuclear Antibody (ANA) Test Market, Forecast 2020-2030
5.3.4.4 Italy Antinuclear Antibody (ANA) Test Market, Forecast 2020-2030
5.3.4.5 Spain Antinuclear Antibody (ANA) Test Market, Forecast 2020-2030
5.3.4.6 The Netherlands Antinuclear Antibody (ANA) Test Market, Forecast 2020-2030
5.3.4.7 Rest of Europe Antinuclear Antibody (ANA) Test Market, Forecast 2020-2030
5.4 Asia-Pacific Antinuclear Antibody (ANA) Test Market Forecast, 2020-2030
5.4.1 Asia-Pacific Antinuclear Antibody (ANA) Test Submarket, By Product Forecast 2020-2030
5.4.2 Asia-Pacific Antinuclear Antibody (ANA) Test Submarket, By Technique Forecast 2020-2030
5.4.3 Asia-Pacific Antinuclear Antibody (ANA) Test Submarket, By Application Forecast 2020-2030
5.4.4 Asia-Pacific Antinuclear Antibody (ANA) Test Submarket, By Country Forecast 2020-2030
5.4.4.1 China Antinuclear Antibody (ANA) Test Market, Forecast 2020-2030
5.4.4.2 India Antinuclear Antibody (ANA) Test Market, Forecast 2020-2030
5.4.4.3 Japan Antinuclear Antibody (ANA) Test Market, Forecast 2020-2030
5.4.4.4 Korea Antinuclear Antibody (ANA) Test Market, Forecast 2020-2030
5.4.4.5 Indonesia Antinuclear Antibody (ANA) Test Market, Forecast 2020-2030
5.4.4.6 Australia Antinuclear Antibody (ANA) Test Market, Forecast 2020-2030
5.4.4.7 Rest of Asia-Pacific Antinuclear Antibody (ANA) Test Market, Forecast 2020-2030
5.5 Rest of World Antinuclear Antibody (ANA) Test Market Forecast, 2020-2030
5.5.1 Rest of World Antinuclear Antibody (ANA) Test Submarket, By Product Forecast 2020-2030
5.5.2 Rest of World Antinuclear Antibody (ANA) Test Submarket, By Technique Forecast 2020-2030
5.5.3 Rest of World Antinuclear Antibody (ANA) Test Submarket, By Application Forecast 2020-2030
6. Leading Companies in The Antinuclear Antibody (ANA) Test Market
6.1 Eagle Biosciences
6.1.1 Eagle Biosciences Overview
6.1.2 Analysis of Eagle Biosciences Products and Services
6.1.3 Eagle Biosciences Primary Market Competitors 2019
6.1.4 Eagle Biosciences Key Developments
6.2 Thermo Fisher Scientific, Inc.
6.2.1 Thermo Fisher Scientific, Inc. Company Overview
6.2.2 Analysis of Thermo Fisher Scientific, Inc. Products and Services
6.2.3 Thermo Fisher Scientific, Inc. Primary Market Competitors 2019
6.2.4 Thermo Fisher Scientific, Inc. Key Developments
6.3 Alere Inc.
6.3.1 Alere Inc. Company Overview
6.3.2 Analysis of Alere Inc. Products and Services
6.3.3 Alere Inc. Primary Market Competitors 2019
6.3.4 Alere Inc. Key Developments
6.4 Trinity Biotech PLC
6.4.1 Trinity Biotech PLC Company Overview
6.4.2 Analysis of Trinity Biotech PLC Products and Services
6.4.3 Trinity Biotech PLC Primary Market Competitors 2019
6.4.4 Trinity Biotech PLC Key Developments
6.5 Bio-Rad Laboratories, Inc
6.5.1 Bio-Rad Laboratories, Inc Company Overview
6.5.2 Analysis of Bio-Rad Laboratories, Inc Products and Services
6.5.3 Bio-Rad Laboratories, Inc Primary Market Competitors 2019
6.5.4 Bio-Rad Laboratories, Inc Key Developments
6.6 Erba Diagnostics, Inc
6.6.1 Erba Diagnostics, Inc Company Overview
6.6.2 Analysis of Erba Diagnostics, Inc Products and Services
6.6.3 Erba Diagnostics, Inc Primary Market Competitors 2019
6.6.4 Erba Diagnostics, Inc Key Developments
6.7 Euroimmun AG
6.7.1 Euroimmun AG Company Overview
6.7.2 Analysis of Euroimmun AG Products and Services
6.7.3 Euroimmun AG Primary Market Competitors 2019
6.7.4 Euroimmun AG Key Developments
6.8 Immuno Concepts
6.8.1 Immuno Concepts Company Overview
6.8.2 Analysis of Immuno Concepts Products and Services
6.8.3 Immuno Concepts Primary Market Competitors 2019
6.8.4 Immuno Concepts Key Developments
6.9 Inova Diagnostics
6.9.1 Inova Diagnostics Company Overview
6.9.2 Analysis of Inova Diagnostics Products and Services
6.9.3 Inova Diagnostics Primary Market Competitors 2019
6.9.4 Inova Diagnostics Key Developments
6.10 Zeus Scientific, Inc.
6.10.1 Zeus Scientific, Inc. Company Overview
6.10.2 Analysis of Zeus Scientific, Inc. Products and Services
6.10.3 Zeus Scientific, Inc. Primary Market Competitors 2019
6.10.4 Zeus Scientific, Inc. Key Developments
7. Conclusions and Recommendations
7.1. Key Research Findings
7.2. Conclusion by Geography
7.3. Conclusion by Solution Type
7.4. Strategic Recommendations
8. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain Report Evaluation Form
List of Figures
Figure 1.1 Global Antinuclear Antibody (ANA) Test Market Segmentation
Figure 2.1 Antinuclear Antibody (ANA) Test Value Chain Analysis
Figure 3.1 Antinuclear Antibody (ANA) Test Supply-Demand Analysis
Figure 4.1 Global Antinuclear Antibody (ANA) Test Forecast 2020-2030 ($billion, AGR %)
Figure 4.2 Global Antinuclear Antibody (ANA) Test Market Forecast 2020-2030
Figure 4.3 Global Antinuclear Antibody (ANA) Test Submarket Forecast by 2020-2030 ($ billion)
Figure 4.4 Global Antinuclear Antibody (ANA) Test Market By Product Share Forecast 2019, 2025, 2029 (% Share)
Figure 4.19 Global Antinuclear Antibody (ANA) Test by Submarket By Product Forecast 2020-2030 ($ million)
Figure 4.20 Global Antinuclear Antibody (ANA) Test Market, by Share Forecast 2019, 2025, 2029 (% Share)
Figure 4.21 Antinuclear Antibody (ANA) Test Market, By Technique Forecast 2020-2030 ($billion, AGR%)
Figure 4.23 Antinuclear Antibody (ANA) Test Market, By Application System Forecast 2020-2030 ($billion, AGR%)
Figure 4.25 Antinuclear Antibody (ANA) Test Market, By Product Forecast 2020-2030 ($billion, AGR%)
Figure 4.27 Antinuclear Antibody (ANA) Test Market, By Technique Forecast 2020-2030 ($billion, AGR%)
Figure 5.1 Regional/Country Antinuclear Antibody (ANA) Test Market, by 2020-2030
Figure 5.3 Leading Country/Regional Antinuclear Antibody (ANA) Test Market Share, by 2020
Figure 5.4 Leading Country/Regional Antinuclear Antibody (ANA) Test Market Share, by 2025
Figure 5.5 Leading Country/Regional Antinuclear Antibody (ANA) Test Market Share, by 2030
Figure 5.6 Europe Antinuclear Antibody (ANA) Test Market Forecast 2020-2030 ($billion, AGR%)
Figure 5.7 Europe Antinuclear Antibody (ANA) Test Market, by Forecast 2020-2030
Figure 5.8 Europe Antinuclear Antibody (ANA) Test Submarket, By Product Forecast 2020-2030
Figure 5.9 Europe Antinuclear Antibody (ANA) Test Submarket , By Technique Forecast 2020-2030
Figure 5.10 Europe Antinuclear Antibody (ANA) Test Submarket , By Country Forecast 2020-2030
Figure 5.11 Europe Antinuclear Antibody (ANA) Test Submarket , By Application 2020-2030 ($billion, AGR%)
Figure 5.10 North America Antinuclear Antibody (ANA) Test Market Forecast 2020-2030 ($billion, AGR%)
Figure 5.11 North America Antinuclear Antibody (ANA) Test Market, by Forecast 2020-2030
Figure 5.12 North America Antinuclear Antibody (ANA) Test Submarket, By Product Forecast 2020-2030
Figure 5.13 North America Antinuclear Antibody (ANA) Test Submarket , By Technique Forecast 2020-2030
Figure 5.14 North America Antinuclear Antibody (ANA) Test Submarket , By Application Forecast 2020-2030
Figure 5.13 North America Antinuclear Antibody (ANA) Test Submarket , By Country Forecast 2020-2030
Figure 5.14 Asia-Pacific Antinuclear Antibody (ANA) Test Market Forecast 2020-2030 ($billion , AGR%)
Figure 5.15 Asia-Pacific Antinuclear Antibody (ANA) Test Market, by Forecast 2020-2030
Figure 5.16 Asia-Pacific Antinuclear Antibody (ANA) Test Submarket, By Product Forecast 2020-2030
Figure 5.17 Asia-Pacific Antinuclear Antibody (ANA) Test Submarket , By Country Forecast 2020-2030
Figure 5.17 Asia-Pacific Antinuclear Antibody (ANA) Test Submarket , By Application Forecast 2020-2030
Figure 5.18 Rest of World Antinuclear Antibody (ANA) Test Market Forecast 2020-2030 ($billion, AGR%)
Figure 5.19 Rest of World Antinuclear Antibody (ANA) Test Market, by Forecast 2020-2030
Figure 5.20 Rest of World Antinuclear Antibody (ANA) Test Submarket, By Product Forecast 2020-2030
Figure 5.21 Rest of World Antinuclear Antibody (ANA) Test Submarket , By Technique Forecast 2020-2030
Figure 5.21 Rest of World Antinuclear Antibody (ANA) Test Submarket , By Application Forecast 2020-2030
Figure 6.1 3M Total Company Sales 2013-2019 (US$ million, AGR %)
Figure 6.2 Thermo Fisher Scientific, Inc. Total Company Sales 2013-2019 (US$ million, AGR %)
Figure 6.3 Alere Inc. Total Company Sales 2013-2019 (US$ Bn, AGR %)
Figure 6.6 Trinity Biotech PLC Company Sales 2013-2019 (US$ bn, AGR %)
Figure 6.7 Trinity Biotech PLC Revenue % Share, by Application Segment, 2019
Figure 6.8 Trinity Biotech PLC Revenue % Share, by Geographical Trade, 2019
Figure 6.9 Trinity Biotech PLC Revenue % Share, by Business Segment, 2019
Figure 6.10 Bio-Rad Laboratories, Inc Revenue % Share, by Geographic Segment, 2019
Figure 6.11 Erba Diagnostics, Inc Company Total Company Sales 2013-2019 (US$ million, AGR %)
Figure 6.12 Euroimmun AG Total Company Sales 2013-2019 (US$ million, AGR %)
Figure 6.13 Euroimmun AG Revenue % Share, by Regional Segment, 2019
Figure 6.14 Immuno Concepts Total Company Sales 2013-2019 (US$ million, AGR %)
Figure 6.15 Immuno Concepts Revenue % Share, by Regional Segment, 2019
Figure 6.16 Immuno Concepts Revenue % Share, by Business Segment, 2019
Figure 6.17 Inova Diagnostics Total Company Sales 2013-2019 (US$ bn, AGR %)
Figure 6.18 Zeus Scientific, Inc. Total Company Revenue 2013-2019 (US$ bn, AGR %)
Figure 6.19 Zeus Scientific, Inc. Company Sales 2014-2019 (US$ bn, AGR %)
Figure 6.20 Zeus Scientific, Inc. Revenue % Share, by Business Segment, 2019
List of Tables
Table 1.0 Research Scope
Table 4.1 Global Antinuclear Antibody (ANA) Test Market Forecast 2020-2030 ($Bn, AGR %, CAGR %)
Table 4.2 Global Antinuclear Antibody (ANA) Test Submarket, By Product Forecast 2020-2030 ($billion, AGR %)
Table 4.3 Global Antinuclear Antibody (ANA) Test Submarket, By Application Forecast 2020-2030 ($billion, AGR %)
Table 5.1 Global Antinuclear Antibody (ANA) Test Market, by Country/Region Forecast 2020-2030 ($billion, AGR %)
Table 5.3 Europe Antinuclear Antibody (ANA) Test Market Forecast 2020-2030 ($billion, , AGR %, CAGR %)
Table 5.4 Europe Antinuclear Antibody (ANA) Test Submarket, By Product Forecast 2020-2030 ($billion, AGR %)
Table 5.5 Europe Antinuclear Antibody (ANA) Test Submarket, By Technique Forecast 2020-2030 ($billion, AGR %)
Table 5.6 North America Antinuclear Antibody (ANA) Test Market Submarket, By Application Forecast 2020-2030 ($billion, , AGR %, CAGR %)
Table 5.7 North America Antinuclear Antibody (ANA) Test Submarket, By Product Forecast 2020-2030 ($billion, AGR %)
Table 5.8 North America Antinuclear Antibody (ANA) Test Submarket, By Technique Forecast 2020-2030 ($billion, AGR %)
Table 5.9 Asia-Pacific Antinuclear Antibody (ANA) Test Market Forecast 2020-2030 ($billion, , AGR %, CAGR %)
Table 5.10 Asia-Pacific Antinuclear Antibody (ANA) Test Submarket, By Product Forecast 2020-2030 ($billion, AGR %)
Table 5.11 Asia-Pacific Antinuclear Antibody (ANA) Test Submarket, By Technique Forecast 2020-2030 ($billion, AGR %)
Table 5.12 Rest of World Antinuclear Antibody (ANA) Test Market Submarket, By Application Forecast 2020-2030 ($billion, , AGR %, CAGR %)
Table 5.13 Rest of World Antinuclear Antibody (ANA) Test Submarket, By Product Forecast 2020-2030 ($billion, AGR %)
Table 5.14 Rest of World Antinuclear Antibody (ANA) Test Submarket, By Technique Forecast 2020-2030 ($billion, AGR %)
Table 6.1 3M Profile 2019 (Market Entry, Public/Private, Headquarters, Geography, Key Market, Listed on, Products/Services
Table 6.2 3M Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)
Table 6.3 3M Products and Services (Product/Service, Segment)
Table 6.4 3M Total Company Sales 2015-2019 (US$billion, AGR %)
Table 6.5 3M Total Company Recent Development 2015-2019
Table 6.6 Thermo Fisher Scientific, Inc. Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)
Table 6.7 Thermo Fisher Scientific, Inc. Products and Services (Product/Service, Segment)
Table 6.8 Thermo Fisher Scientific, Inc. Total Company Sales 2015-2019 (US$billion, AGR %)
Table 6.9 Thermo Fisher Scientific, Inc. Total Company Recent Development 2015-2019
Table 6.10 Alere Inc. Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)
Table 6.11 Alere Inc. Products and Services (Product/Service, Segment)
Table 6.12 Alere Inc. Total Company Sales 2015-2019 (US$billion, AGR %)
Table 6.13 Alere Inc. Total Company Recent Development 2015-2019
Table 6.14 Trinity Biotech PLC Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)
Table 6.15 Trinity Biotech PLC Products and Services (Product/Service, Segment)
Table 6.16 Trinity Biotech PLC Total Company Sales 2015-2019 (US$billion, AGR %)
Table 6.17 Trinity Biotech PLC Total Company Recent Development 2015-2019
Table 6.18 Bio-Rad Laboratories, Inc Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)
Table 6.19 Bio-Rad Laboratories, Inc Products and Services (Product/Service, Segment)
Table 6.20 Bio-Rad Laboratories, Inc Total Company Sales 2015-2019 (US$billion, AGR %)
Table 6.21 Bio-Rad Laboratories, Inc Total Company Recent Development 2015-2019
Table 6.22 Erba Diagnostics, Inc Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)
Table 6.23 Erba Diagnostics, Inc Products and Services (Product/Service, Segment)
Table 6.24 Erba Diagnostics, Inc Total Company Sales 2015-2019 (US$billion, AGR %)
Table 6.25 Erba Diagnostics, Inc Total Company Recent Development 2015-2019
Table 6.26 Euroimmun AG Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)
Table 6.27 Euroimmun AG Products and Services (Product/Service, Segment)
Table 6.28 Euroimmun AG Total Company Sales 2015-2019 (US$billion, AGR %)
Table 6.29 Euroimmun AG Total Company Recent Development 2015-2019
Table 6.30 Immuno Concepts Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)
Table 6.31 Immuno Concepts Products and Services (Product/Service, Segment)
Table 6.32 Immuno Concepts Total Company Sales 2015-2019 (US$billion, AGR %)
Table 6.33 Immuno Concepts Total Company Recent Development 2015-2019
Table 6.34 Inova Diagnostics Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)
Table 6.35 Inova Diagnostics Products and Services (Product/Service, Segment)
Table 6.36 Inova Diagnostics Total Company Sales 2015-2019 (US$billion, AGR %)
Table 6.37 Inova Diagnostics Total Company Recent Development 2015-2019
Table 6.38 Zeus Scientific, Inc. Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)
Table 6.39 Zeus Scientific, Inc. Products and Services (Product/Service, Segment)
Table 6.40 Zeus Scientific, Inc. Total Company Sales 2015-2019 (US$billion, AGR %)
Table 6.41 Zeus Scientific, Inc. Total Company Recent Development 2015-2019
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
